Daewoong Pharmaceutical's Luphere and Takeda Pharmaceutical Leuplin are leading the market in the field of prostate cancer treatment. According to the drug distribution performance data, Luphere and Leuplin ranked 1st and 2nd based on single product sales in the first half of this year, with a performance of 15.4 billion won and 13.9 billion won, respectively. In the last five years, these two products have been fiercely competing for a leading position.

In 2019-2020, Leuplin surpassed Luphere, which recorded 21.5 billion and 22.4 billion won at 32.2 billion and 315 billion won, and in 2021 and 2022, Luphere surpassed Leuplin, which achieved 242 billion and 27.5 billion won with 30.7 billion and 30.4